SBIR Phase II funding will advance development of Matrix stabilization platform.
CAMBRIDGE, Massachusetts—October 20th, 2016 — Vaxess Technologies, Inc., an innovative life sciences company developing novel stabilization and delivery technologies, was awarded a highly competitive Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). Funding totaling $750,000 will go toward the development of novel heat-stable vaccine and novel delivery presentation formats.
Phase II funding was awarded following successfully reaching SBIR Phase I endpoints and milestones, including the development of a highly stable formulation of rotavirus vaccine in a novel quickly dissolvable thin oral film format.
“Building on the success of the Phase I program, we will continue the development of heat stable vaccine products and novel delivery formats to reach global vaccine coverage,” said Vaxess Vice President of Policy and Strategy Livio Valenti. “NSF funds are critical for the advancement of the Matrix stabilization platform and its extension to several high-potential vaccine target and novel delivery formats.”
About Vaxess Technologies
Vaxess was founded in 2012 around technologies from Tufts University and MIT and has combined venture capital funding with grants and pharmaceutical partnerships to advance development of two main technology platforms.
Matrix is Vaxess’s biologics formulation and drying platform to eliminate the need for cold chain storage and shipment of vaccines, diagnostics reagents and biospecimens.
Vaxess’s Mimix (TM) platform is a novel sustained-release silk microneedle for vaccine delivery and enhanced product efficacy.